Joshua M. Eizen

CIK: 0001949621

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (41.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (41.7%)

Compensation grants

Other (G, F, J, C, D, …)2 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ANTX

AN2 Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

ANTX
AN2 Therapeutics, Inc.
Jul 8, 2026
Sale(S)
Direct
5.9K shares at avg. $4.17$25K
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (right to buy)
Direct
50.2K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Award(A)
Stock Option (right to buy)
Direct
92K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Award(A)
Stock Option (right to buy)
Direct
50.2K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (right to buy)
Direct
92K shares-
ANTX
AN2 Therapeutics, Inc.
Feb 20, 2026
Award(A)
Direct
50K shares-
ANTX
AN2 Therapeutics, Inc.
Jan 6, 2026
Sale(S)
Direct
6.9K shares at avg. $1.01$7K
ANTX
AN2 Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
17.9K shares at avg. $1.00$18K
ANTX
AN2 Therapeutics, Inc.
Nov 4, 2025
Sale(S)
Direct
2.8K shares at avg. $1.14$3K
ANTX
AN2 Therapeutics, Inc.
Feb 26, 2025
Award(A)
Direct
58.5K shares-
ANTX
AN2 Therapeutics, Inc.
Jan 3, 2025
Sale(S)
Direct
9.7K shares at avg. $1.34$13K
ANTX
AN2 Therapeutics, Inc.
Nov 4, 2024
Award(A)
Direct
31.5K shares-

		Type	Shares	Price		Ownership
Jul 8, 2026	ANTX AN2 Therapeutics, Inc.	Sale(S)	5,945	$4.17	$24,803	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	50,150	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Award(A) Stock Option (right to buy)	92,000	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Award(A) Stock Option (right to buy)	50,150	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	92,000	-	-	Direct
Feb 20, 2026	ANTX AN2 Therapeutics, Inc.	Award(A)	50,000	-	$0	Direct
Jan 6, 2026	ANTX AN2 Therapeutics, Inc.	Sale(S)	6,931	$1.01	$7,014	Direct
Jan 5, 2026	ANTX AN2 Therapeutics, Inc.	Sale(S)	17,923	$1.00	$17,948	Direct
Nov 4, 2025	ANTX AN2 Therapeutics, Inc.	Sale(S)	2,819	$1.14	$3,214	Direct
Feb 26, 2025	ANTX AN2 Therapeutics, Inc.	Award(A)	58,500	-	-	Direct
Jan 3, 2025	ANTX AN2 Therapeutics, Inc.	Sale(S)	9,663	$1.34	$12,958	Direct
Nov 4, 2024	ANTX AN2 Therapeutics, Inc.	Award(A)	31,500	-	$0	Direct

1-12 of 12 transactions

About Eizen Joshua M

Eizen Joshua M (SEC CIK 0001949621) files insider reports with the SEC as Officer of AN2 Therapeutics, Inc. (ANTX).

Signal8 holds 8 ownership filings by Eizen Joshua M, all Form 4s, filed between Nov 5, 2024 and Jul 10, 2026. Those filings report 12 transactions, from Nov 4, 2024 to Jul 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Eizen Joshua M's filings is in MENLO PARK, CA.

Recent filings by Eizen Joshua M

Jul 8, 2026: Open-market sale of ANTX shares (Form 4, code S).
Mar 19, 2026: Disposition to issuer transaction of ANTX derivative securities (Form 4, code D).
Mar 19, 2026: Grants or awards of ANTX derivative securities (2 lines, Form 4, code A).
Mar 19, 2026: Disposition to issuer transaction of ANTX derivative securities (Form 4, code D).
Feb 20, 2026: Grant or award of ANTX shares (Form 4, code A).

Other insiders filing for AN2 Therapeutics, Inc. (ANTX)

Marks Gilbert Lynn, Director
Martin Patricia A., Director
Aziz Kabeer, Director
Trenor Cameron C. III, Chief Medical Officer
Readnour Robin Shane, Director
Williams Sarah Joanne, Principal Accounting Officer

How to read Form 4 transaction codes